Onconova scientists present rigosertib data at American Society of Hemotology's 57th annual meeting
The Onconova representatives spoke about data and results gleaned from the Phase 1/2 clinical trial they did on oral rigosertib and azacitidine, a therapy they believe could be used in the treatment regimen of patients with melodysplastic syndromes (HR-MDS).
“The high response rate observed in the 09-08 combination trial is impressive,” Dr. Lewis Silverman, investigator in the trial, said. “Furthermore, the tolerability profile of oral rigosertib and azacitidine suggests that this combination could be used in HR-MDS."
The average age for the 30 test subjects was 64. Most tolerated the therapy well. They all received the treatment for four months; 23 responded positively. Six went into complete remission.
“The results for oral rigosertib in combination with azacitidine support moving this novel therapy toward pivotal trials for patients with MDS and myeloid malignancies," Dr. Ramesh Kumar, Onconova's president and CEO, said. “We intend to provide clarity related to timing of further development for oral rigosertib at our upcoming investor event on Dec. 16.”
A webcast to review the clinical data from the study will take place at 8 a.m. EST on Dec. 16. To view the webcast, log on to www.onconova.com and click the "Events and Presentations" tab.
Organizations in this story
Onconova Therapeutics 375 Pheasant Run Newtown, PA 18940